Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic

Crippa, José Alexandre de Souza; Zuardi, Antônio Waldo; Guimarães, Francisco Silveira; Campos, Alline C.; Osório, Flávia de Lima; Loureiro, Sônia Regina; Santos, Rafael G. dos; Souza, José Diogo S.; Ushirohira, Juliana Mayumi; Pacheco, Juliano Abreu; Ferreira, Rafael; Costa, Karla Cristinne Mancini; Scomparin, Davi Silveira; Scarante, Franciele Franco; Pires-Dos-Santos, Isabela; Mechoulam, Raphael; Kapczinski, Flávio; Fonseca, Benedito Antônio Lopes da; Espósito, Danillo Lucas Alves; Pereira-Lima, Karina; Sen, Srijan; Andraus, Maristela Haddad; Hallak, Jaime E. C.; Litcanov, Debora Cristina; Rodrigues, Leonardo; Alves, Thiago F.; Coutinho, Barbara Marques

doi:10.1001/jamanetworkopen.2021.20603

Cited by 57 publications

(51 citation statements)

References 35 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an open‐label, single‐site, randomized clinical trial, the safety and efficacy of CBD therapy for the reduction of emotional exhaustion and burnout symptoms among frontline healthcare professionals working with patients with COVID‐19 was investigated. The results indicated that CBD therapy reduced the symptoms of burnout and emotional exhaustion 167 . However, further double‐blind, placebo‐controlled clinical trials are needed to confirm those results.…”

Section: Therapeutical Potential In the Covid‐19mentioning

confidence: 93%

See 1 more Smart Citation

A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)

Peng

Fan

et al. 2022

Basic Clin Pharma Tox

101

View full text Add to dashboard Cite

Cannabidiol (CBD) is an abundant non‐psychoactive phytocannabinoid in cannabis extracts which has high affinity on a series of receptors, including Type 1 cannabinoid receptor (CB1), Type 2 cannabinoid receptor (CB2), GPR55, transient receptor potential vanilloid (TRPV) and peroxisome proliferator‐activated receptor gamma (PPARγ). By modulating the activities of these receptors, CBD exhibits multiple therapeutic effects, including neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti‐inflammatory, analgesic and anticancer properties. CBD could also be applied to treat or prevent COVID‐19 and its complications. Here, we provide a narrative review of CBD's applications in human diseases: from mechanism of action to clinical trials.

show abstract

Section: Therapeutical Potential In the Covid‐19mentioning

confidence: 93%

“…The results indicated that CBD therapy reduced the symptoms of burnout and emotional exhaustion. 167 However, further double-blind, placebocontrolled clinical trials are needed to confirm those results.…”

Section: Therapeutical Potential In the Covid-19mentioning

confidence: 99%

A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)

Peng

Fan

et al. 2022

Basic Clin Pharma Tox

101

View full text Add to dashboard Cite

show abstract

“…The authors reported that in none of these participants, the increase of total bilirubin was more than twofold. No increases were seen in the controls (Crippa et al., 2021 ).…”

Section: Limitations and Uncertainties In Scientific Literaturementioning

confidence: 98%

“…( 2019 ), in subjects given either placebo or single doses of 400 or 800 mg CBD (corresponding to ~ 5 and 10 mg/kg bw) on 3 consecutive days, diarrhoea was reported by 0%, 7.1% and 23% of the respective groups. In the three other randomised control trials, diarrhoea was not observed at acute CBD doses of 5 and 10 mg/kg bw per day (Perkins et al., 2020 ) and of 200, 400 and 800 mg/day (Arout et al., 2022 ) or at a CBD intake of 300 mg per day (divided in two doses) over 4 weeks (Crippa et al., 2021 ).…”

Section: Limitations and Uncertainties In Scientific Literaturementioning

confidence: 99%

Statement on safety of cannabidiol as a novel food: data gaps and uncertainties

Turck¹,

Bohn²,

Castenmiller³

et al. 2022

EFS2

View full text Add to dashboard Cite

The European Commission has determined that cannabidiol (CBD) can be considered as a novel food (NF), and currently, 19 applications are under assessment at EFSA. While assessing these, it has become clear that there are knowledge gaps that need to be addressed before a conclusion on the safety of CBD can be reached. Consequently, EFSA has issued this statement, summarising the state of knowledge on the safety of CBD consumption and highlighting areas where more data are needed. Literature searches for both animal and human studies have been conducted to identify safety concerns. Many human studies have been carried out with Epidyolex ® , a CBD drug authorised to treat refractory epilepsies. In the context of medical conditions, adverse effects are tolerated if the benefit outweighs the adverse effect. This is, however, not acceptable when considering CBD as a NF. Furthermore, most of the human data referred to in the CBD applications investigated the efficacy of Epidyolex (or CBD) at therapeutic doses. No NOAEL could be identified from these studies. Given the complexity and importance of CBD receptors and pathways, interactions need to be taken into account when considering CBD as a NF. The effects on drug metabolism need to be clarified. Toxicokinetics in different matrices, the half‐life and accumulation need to be examined. The effect of CBD on liver, gastrointestinal tract, endocrine system, nervous system and on psychological function needs to be clarified. Studies in animals show significant reproductive toxicity, and the extent to which this occurs in humans generally and in women of child‐bearing age specifically needs to be assessed. Considering the significant uncertainties and data gaps, the Panel concludes that the safety of CBD as a NF cannot currently be established.

show abstract

“…Inhaled CBD can boost serum THC concentration, potentially resulting in increased psychoactive effects [ 28 ]. In a recent study of CBD administered to 120 frontline healthcare professionals who experienced burnout related to COVID-19, adverse events of increased liver function tests were observed in 4 of the 59 subjects receiving CBD 150 mg twice daily over a period of 28 days [ 53 ]. About 20% of the cohort were on psychiatric medications or used weekly alcohol, but not further specified.…”

Section: Risks Associated With Cbdmentioning

confidence: 99%

Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain)

2022

View full text Add to dashboard Cite

Purpose of Review This review will address the many uncertainties surrounding the medical use of cannabidiol (CBD). We will begin with an overview of the legal and commercial environment, examine recent preclinical and clinical evidence on CBD, explore questions concerning CBD raised by healthcare professionals and patients, investigate dosing regimens and methods of administration, and address current challenges in the accumulation of sound evidence. Recent Findings CBD has potential for relief of symptoms of pain, sleep, and mood disturbance in rheumatology patients, but sound clinical evidence is lacking. CBD is safe when accessed from a regulated source, whereas wellness products are less reliable regarding content and contaminants. Dosing for symptom relief has not yet been established. Summary As many rheumatology patients are trying CBD as a self-management strategy, the healthcare community must urgently accrue sound evidence for effect.

show abstract

Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic

Cited by 57 publications

References 35 publications

A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)

A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)

Statement on safety of cannabidiol as a novel food: data gaps and uncertainties

Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain)

Contact Info

Product

Resources

About